Europe Renal Denervation Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029

The European renal denervation devices market was valued at USD 56.92 million in the base year and is expected to register a CAGR of 37.36% over the forecast period.

The pandemic impacted the European renal denervation devices market initially. With the outbreak of COVID-19, the European renal denervation devices market experienced a moderate decline in growth. It was primarily due to the temporary cancellation of treatment and elective procedures of the non-COVID medical condition, such as cardiology and vascular procedures, which includes renal denervation procedures. The pandemic shifted most of the focus of healthcare and research on COVID-19-related diagnosis and treatment, adversely impacting the region's cardiology and vascular specialties. For instance, a study published in the European Heart Journal - Quality of Care and Clinical Outcomes by researchers of Keele University, United Kingdom, in May 2021 highlighted the significant decrease in cardiac procedures in the United Kingdom. The study stated that 45,000 procedures were postponed amid the pandemic. However, in the post-pandemic period, the number of COVID-19-positive patients decreased. Also, the lifting of the lockdown and gradual resumption of the elective procedure of the cardiology, vascular, and other non-COVID medical areas are expected to restore the normal growth rate of the market. For instance, a study published in the European Journal of Vascular and Endovascular Surgery in October 2022 highlighted the recovery and resumption of vascular procedures after the pandemic in the region. The study mentioned that most of the services have rebounded to the pre-pandemic level with the introduction of protocols for the management of the peri-operative COVID-19 risk. Thus, the COVID-19 outbreak adversely impacted the market's growth in its preliminary phase. Moreover, the market is expected to grow at a stable pace with the increasing number of procedures for renal denervation in Europe.

Furthermore, the market is expected to grow, owing to the factors, such as technological advancements, the rising prevalence of hypertension, and the long-lasting effects of the renal denervation procedure.

The prevalence of hypertension is on the rise in the European Region, which is expected to create more demand for renal denervation procedures and devices for the management of the fatality of the disease. For instance, as per the data published by the British Heart Foundation in April 2023, more than 10 million individuals in the United Kingdom have been diagnosed with high blood pressure in 2022. The adversity of the high burden of hypertension is also found in the young population as well in the regions. The renal denervation procedure has been demonstrated to be highly efficient for the long-term management of hypertension. Thus, with such benefits, efficacy, and safety of renal denervation procedures for managing hypertension, the demand for renal denervation devices is likely to increase as more procedures are performed in Europe.

Additionally, another study published in the Clinical Research in Cardiology by the researchers of Erasmus University Medical Center, the Netherlands, in July 2022 underlined the high significance of renal denervation procedure in decreasing the blood pressure of hypertension patients in a few months and putting them off of the antihypertensive drugs. The study demonstrated that the renal denervation procedure maintained the blood pressure for five years in the operated hypertension patients. The procedure also decreased the ambulatory daytime without antihypertensive drug therapy over the period. Further, a study published in the Journal of Medicine by researchers at Vilnius University, Lithuania, highlighted the long-term antihypertensive effects of renal denervation. Thus, with the increasing cases of hypertension and the long-term benefits of renal denervation, the market for renal denervation devices is expected to grow further during the forecast period in Europe.

However, the painful procedure and stringent approval process for renal denervation devices and reimbursement systems will likely impede market growth.

Europe Renal Denervation Devices Market Trends

The Ultrasound-based Segment is Expected to Witness Significant Growth Over the Forecast Period

The ultrasound-based renal denervation devices use ultrasound to ablate nerves in the wall of the renal arteries in minimally invasive procedures. It disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure.

The ultrasound-based renal denervation devices are expected to grow in the market, owing to the high prevalence of hypertension, stress, and the benefits of ultrasound-based renal denervation for managing the disease. Several research studies have highlighted the efficacy of ultrasound-based renal denervation devices for managing hypertension, which is anticipated to attract more patient demand and support the market players to offer more ultrasound-based renal denervation devices. These factors are expected to boost the growth of the segment. For instance, a study published in the EuroIntervention in 2021 demonstrated the proven efficacy of lowering blood pressure by ultrasound-based renal denervation in patients.

Further, in a study published in the Journal Lancet in May 2021, ultrasound renal denervation decreased the blood pressure within two months of the procedure of hypertensive patients resistant to triple combination pills. The triple combination pill consisted of anti-hypertensive drugs, including a calcium channel blocker, a thiazide diuretic, and an angiotensin receptor blocker. These studies demonstrated ultrasound-based renal denervation for managing anti-hypertensive drugs resistant patients. Thus, ultrasound renal denervation can be a highly effective treatment for resistant anti-hypertensive drugs.

Additionally, several factors are associated with hypertension in European countries which is believed to boost segment growth. For instance, stress is one of the key factors for hypertension in the young population. The Labor Force Survey conducted in November 2022 in the United Kingdom indicated that around 914 per 1,000 young individuals were having work-related stress in the country which is leading to the conditions, such as hypertension.

Therefore, the ultrasound-based segment is expected to witness a significant growth over the forecast period due to the rising prevalence of hypertension and the effectiveness of ultrasound-based therapies in managing the same.

Germany is Expected to Dominate the Europe Renal Denervation Devices Market

Germany is expected to dominate the market owing to factors such as the high prevalence of hypertension, highly advanced medical and research infrastructure, and key developments by the market players in the country.

The country has a significant hypertension burden associated with the serious medical issue of high blood pressure, elevated risk of stroke, kidney disease, and heart failure. These issues are expected to increase the need for renal denervation procedures, which is likely to boost the demand for renal denervation devices and boost the segment's growth. For instance, a study published in the journal Original Cardiovascular in 2022 mentioned that Germany recorded 161,261 heart surgeries in 2021. Such a high volume of heart surgeries reflects the severity of the cardiac issues which are contributed by hypertension, which renal denervation procedures can control. Thus, such a high burden of cardiac disease is expected to drive the segment's growth in the coming years.

Furthermore, the key developments in Germany are also expected to boost the market in the country, which is likely to increase the market penetration in the country. For instance, in October 2021, ReCor Medical Inc. launched the ultrasound renal denervation system in Europe, which is being used to treat uncontrolled hypertension in Germany.

Therefore, owing to the factors above, including the significant burden of cardiac diseases driven by hypertension and the recent developments by the market players, the growth of the market studied is anticipated in Germany.

Europe Renal Denervation Devices Industry Overview

The European renal denervation devices market is moderate in nature due to the presence of a few companies operating in the region. The key players operating in the market include, Medtronic, Abbott (St. Jude Medical Inc.), ReCor Medical Inc., Mercator MedSystems, and Terumo Corporation.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support